GAMMAGARD LGA Trademark

Trademark Overview

On Friday, October 7, 2022, a trademark application was filed for GAMMAGARD LGA with the United States Patent and Trademark Office. The USPTO has given the GAMMAGARD LGA trademark a serial number of 97623689. The federal status of this trademark filing is FIFTH EXTENSION - GRANTED as of Tuesday, May 5, 2026. This trademark is owned by Baxalta Incorporated. The GAMMAGARD LGA trademark is filed in the Pharmaceutical Products category with the following description:

Immunoglobulin for subcutaneous and intravenous administration to humans
gammagard lga

General Information

Serial Number97623689
Word MarkGAMMAGARD LGA
Filing DateFriday, October 7, 2022
Status734 - FIFTH EXTENSION - GRANTED
Status DateTuesday, May 5, 2026
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, June 20, 2023

Trademark Statements

Goods and ServicesImmunoglobulin for subcutaneous and intravenous administration to humans

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, October 24, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameBaxalta Incorporated
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressBannockburn, IL 60015
US
Party NameBaxalta Incorporated
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressBannockburn, IL 60015
US

Trademark Events

Event DateEvent Description
Tuesday, October 11, 2022NEW APPLICATION ENTERED
Monday, October 24, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, May 9, 2023ASSIGNED TO EXAMINER
Thursday, May 11, 2023NON-FINAL ACTION WRITTEN
Thursday, May 11, 2023NON-FINAL ACTION E-MAILED
Thursday, May 11, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, May 12, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, May 12, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Saturday, May 13, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, May 15, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, May 31, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, June 20, 2023PUBLISHED FOR OPPOSITION
Tuesday, June 20, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, August 15, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Friday, January 19, 2024SOU TEAS EXTENSION RECEIVED
Friday, January 19, 2024SOU EXTENSION 1 FILED
Friday, January 19, 2024SOU EXTENSION 1 GRANTED
Tuesday, January 23, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, June 18, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, June 18, 2024SOU EXTENSION 2 FILED
Tuesday, June 18, 2024SOU EXTENSION 2 GRANTED
Tuesday, June 18, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, January 31, 2025SOU TEAS EXTENSION RECEIVED
Friday, January 31, 2025SOU EXTENSION 3 FILED
Friday, January 31, 2025SOU EXTENSION 3 GRANTED
Saturday, February 1, 2025NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, May 28, 2025SOU TEAS EXTENSION RECEIVED
Wednesday, May 28, 2025SOU EXTENSION 4 FILED
Wednesday, May 28, 2025SOU EXTENSION 4 GRANTED
Monday, September 15, 2025NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, November 19, 2025TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Wednesday, November 19, 2025ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Wednesday, November 19, 2025TEAS CHANGE OF CORRESPONDENCE RECEIVED
Monday, December 1, 2025SOU TEAS EXTENSION RECEIVED
Tuesday, May 5, 2026CASE ASSIGNED TO INTENT TO USE PARALEGAL
Sunday, November 30, 2025SOU EXTENSION 5 FILED
Tuesday, May 5, 2026SOU EXTENSION 5 GRANTED
Wednesday, May 6, 2026NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

Related Keywords

gammagard humans administration intravenous subcutaneous immunoglobulin